

**FANCONI CANADA**  
Unaudited Financial Statements  
December 31<sup>st</sup>, 2010

Prepared By:

Annette Waxberg  
Treasurer

June 30, 2011

**FANCONI CANADA****Statement of Financial Position**  
(Unaudited)

As at December 31, 2010

	<u>Dec. 31, 2010</u>	<u>Dec. 31, 2009</u>
<b>CURRENT ASSETS</b>		
Bank accounts	\$254,137	\$97,110
GIC and other current assets	119,950	245,827
<b>TOTAL CURRENT ASSETS</b>	<u>\$374,087</u>	<u>\$342,937</u>
<b>LIABILITIES &amp; NET ASSETS</b>		
Payables	\$1,773	\$198
Net Assets internally restricted for research (note 3)	335,213	322,158
Unrestricted net assets	37,101	20,581
<b>TOTAL LIABILITIES &amp; NET ASSETS</b>	<u>\$374,087</u>	<u>\$342,937</u>

June 30, 2011

**FANCONI CANADA****Statement of Operations**  
(Unaudited)

For the year ended December 31, 2010

	Jan. 1, 2010 to <u>Dec. 31, 2010</u>	Jan. 1, 2009 to <u>Dec. 31, 2009</u>
<b>REVENUES</b>		
Research contributions	\$139,881	\$119,641
Unrestricted contributions	3,285	806
Interest income	15,612	8,596
Total revenues	<u>\$158,778</u>	<u>\$129,043</u>
<b>GRANTS &amp; EXPENSES</b>		
Research projects funded (notes 4 to 10)	\$90,229	\$36,166
Direct Fundraising expenses	35,597	31,342
Administrative expenses	3,377	2,687
Total grants & expenses	<u>\$129,203</u>	<u>\$70,195</u>
<b>Excess &lt;deficit&gt; of revenues over grants &amp; expenses</b>	<u>\$29,575</u>	<u>\$58,848</u>

June 30, 2011

**FANCONI CANADA****Statement of Changes in Net Assets**  
(Unaudited)

As at Dec. 31, 2010

	<u>Internally Restricted for Research</u>	<u>Unrestricted</u>	<u>Dec. 31, 2010</u>	<u>Dec. 31, 2009</u>
<b>NET ASSETS</b>				
Balance, beginning of year	\$322,158	\$20,581	\$342,739	\$283,891
Excess <deficit> of revenues over expenses, research	14,055		14,055	52,133
Excess <deficit> of expenses over revenues, administration		15,520	15,520	6,715
<b>BALANCE, END OF YEAR</b>	<u>\$336,213</u>	<u>\$36,101</u>	<u>\$372,314</u>	<u>\$342,739</u>

June 30, 2011

**FANCONI CANADA****Statement of Cash Flows**  
(Unaudited)

For the year ended December 31, 2010

	<u>Jan. 1, 2010 to</u> <u>Dec. 31, 2010</u>	<u>Jan. 1, 2009 to</u> <u>Dec. 31, 2009</u>
<b>Cash flows from operating activities</b>		
Net fundraising for research (note 4):		
Ontario Fundraiser 2010	\$70,214	
Scotiabank Waterfront Run 2010	10,926	
General Donations	8,798	
LAWPRO Employee Fundraising	5,604	
Lauzier Family Fundraiser	3,511	
Kestenberg Siegel Lipkus Casual Days	2,400	
Tribute Cards	2,633	
	<hr/>	
	104,086	\$88,299
Administrative contributions	3,285	806
Interest	15,612	8,596
Research projects:		
Huard (note 5)	-	<4,375>
Vignard (note 6)	<22,500>	1,667
Jones (note 7)	<22,500>	<20,833>
Mistry (note 8)	<11,000>	<10,125>
Larin (note 9)	<6,625>	-
Kaddar (note 10)	<22,500>	-
St-Laurent Pedneault (note 11)	<5,104>	-
Other research projects	-	<2,500>
Administrative costs	<3,179>	<2,687>
Net increase <decrease> in payables	1,575	273
<b>Net cash generated through operating activities</b>	<hr/>	
	31,150	59,121
<b>Cash flows from financing &amp; investing activities</b>	-	-
Cash & GIC's, beginning of year	342,937	283,816
<b>Cash &amp; GIC's, end of year</b>	<hr/>	
	\$374,087	\$342,937

**FANCONI CANADA****Notes to Financial Statements**  
(Unaudited)

As at December 31, 2010

**1. Purpose of the Organization**

Fanconi Canada (Canadian Fanconi Anemia Research Fund/La Fondation Canadienne de Recherche de L'Anemie de Fanconi) raises money to fund research on finding a cure and/or treatment for Fanconi Anemia (a fatal genetic disease causing bone marrow failure and physical anomalies); to raise awareness among members of the general public and the medical community about Fanconi Anemia, its diagnosis and methods of treatment; to provide support to Canadian families affected by Fanconi Anemia; and the publication of newsletters and educational materials in furtherance of the foregoing objectives. Fanconi Canada is incorporated under the Canada Corporations Act as a not-for-profit organization and is a registered charity under the Income Tax Act.

**2. Significant Accounting Policies****Revenue recognition**

Fanconi Canada follows the deferral method of accounting for contributions. Restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Unrestricted investment income is recognized as revenue when earned.

**Investments**

Investments are recorded at the lower of cost and market value.

**Contributed services**

Volunteers contribute many hours per year to assist Fanconi Canada in carrying out its service delivery activities, fundraising and day-to-day operations. Because of the difficulty of determining their fair value, contributed services are not recognized in the financial statements.

### **3. Restrictions on net assets**

Fanconi Canada has no net assets with externally imposed restrictions; however, donations from the public are internally restricted to be used for research. Some donations from families afflicted with Fanconi Anemia are directed to cover Fanconi Canada services and administrative expenses, which are also covered by interest revenue.

### **4. Statement of Cash Flows**

The item 'Net fundraising for research' was broken down on a different basis in previous years, so comparative data are not available for 2009.

### **5. Contractual Obligations – Caroline Huard**

A Doctoral Research award was granted to Caroline Huard at Université Laval de Quebec for the project titled *Rôle du corépresseur de la transcription ctBPI (C-terminal binding protein) dans l'anémie de Fanconi* under the CIHR Small Health Organization Partnership Program for 2006. Fanconi Canada's obligation is for one half of \$22,000 per year for two years, commencing September 1, 2007.

### **6. Contractual Obligations – Julien Vignard**

A Post-Doctoral Fellowship in FA Research in partnership with CIHR for the 2007 Competition was awarded to Julien Vignard of Laval University in Quebec City for his project studying the role of FA proteins in DNA double-stranded break repair. Fanconi Canada's obligation is for one half of \$45,000 per year for three years commencing April 2008. Subsequently, he postponed his CIHR funding to the period May 1, 2009 to April 30, 2012. Finally, his funding will be terminated early on August 15, 2011, due to his return to France.

### **7. Contractual Obligations – Dr. Martin R. Jones**

The Canadian Institutes of Health Research/Fanconi Canada Post-Doctoral Fellowship in FA Research (under the 2008 CIHR Small Health Organization Partnership Program) was awarded to Dr. Martin R. Jones of the University of British Columbia. Dr. Jones' project is titled *Characterization of Fanconi anemia and a FA genetic network in C. elegans: A model for developing Fanconi Anemia therapeutic targets*. This three year fellowship has a value of \$135,000 which will be funded equally by CIHR and Fanconi Canada from May 1, 2009 to April 30, 2012.

## **8. Contractual Obligations – Helena S. Mistry**

Helena S. Mistry of the Hospital for Sick Children in Toronto received the Canadian Institutes of Health Research/Fanconi Canada Doctoral Research Award in FA Research (under the 2008 CIHR Small Health Organization Partnership Program). Dr. Mistry's project is titled *Relationship of Mus81-Eme1 to Fanconi Anemia signaling I the DNA damage response*. This two year fellowship has a value of \$44,000 which will be funded equally by CIHR and Fanconi Canada from May 1, 2009 to April 30, 2011.

## **9. Contractual Obligations – Meghan E. Larin**

Fanconi Canada in partnership with the Canadian Institutes of Health Research, has agreed to fund a three-year doctoral research award to Meghan E. Larin of the University of Toronto, Department of Pharmacology and Toxicology for her project entitled *Fanconi Anemia signaling and Mus81-Eme1: role in replicative stress and development*. The award is for \$22,000 per year for a total of \$66,000 funded equally by Fanconi Canada and CIHR from September 1, 2010 to August 31, 2013.

## **10. Contractual Obligations – Tagrid Kaddar**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2009 CIHR Small Health Organization Partnership Program), has granted a three-year Fellowship Award to Tagrid Kaddar of Université Laval, Québec to study the role of Fanconi proteins in hematopoiesis. The award is for \$45,000 per year for a total of \$135,000 funded equally by Fanconi Canada and CIHR from September 1, 2010 to August 31, 2013.

## **11. Contractual Obligations – Christopher W. St-Laurent Pedneault**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2009 CIHR Small Health Organization Partnership Program), has granted a one year Master's Award to Christopher St-Laurent Peneault of Université Laval, Québec to study functional splice variants in FANCA cells and their effects on DNA repair. The award is for \$17,500, funded equally by Fanconi Canada and CIHR from September 1, 2010 to August 31, 2011.

## **12. Contractual Obligations – David Howe Kwan**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2010 CIHR Small Health Organization Partnership Program), has granted a three-year Fellowship Award to David Howe Kwan of the University of British Columbia for his project *Improving Enzymatic Removal of Major Blood Antigens* to help improve the availability and safety of blood transfusions. The award is for \$45,000 per year for a total of \$135,000 funded equally by Fanconi Canada and CIHR from May 1, 2011 to April 30, 2014.

## **13. Contractual Obligations – Maja Tarailo-Graovac**

Fanconi Canada in partnership with the Canadian Institutes of Health Research (under the 2010 CIHR Small Health Organization Partnership Program), has granted a two year Fellowship Award to Maja Tarailo-Graovac of Simon Fraser University for the *project Genome Variations that Drive Increased Fitness in MAD1 and FANC-J-Defective C. elegans* which could add to the knowledge regarding the cause of Fanconi anemia as well as causation and development of cancer in general. The award was originally announced for \$78,750, funded equally by Fanconi Canada and CIHR from April 1, 2011 to Dec. 31, 2012. Subsequently, due to a request for maternity leave, the project end date was extended to May 31, 2013 and funding increased to \$95,417, the difference of \$16,667 being fully funded by CIHR.

## **14. Contractual Obligations – SHOPP 2011 Competition**

Fanconi Canada in partnership with the Canadian Institutes of Health Research has announced four competitions under the Small Health Organizations Partnership Program (SHOPP) 2011 to be funded equally by Fanconi Canada and CIHR. The joint commitment is potentially for \$697,500 over the next six years covering a Masters Award, a Doctoral Research Award, a Fellowship Award and a New Investigator Award to start April 1, 2012, with Funding Decisions to be announced starting in February 2012 and ending April 2012.

June 30, 2011

**15. Ontario Fundraiser**

The following is a breakdown of the 10<sup>th</sup> Annual Ontario Fundraiser, the major fundraising initiative for Fanconi Canada.

**Ontario Fundraiser  
Amount Raised for Research  
(Unaudited)**

For the year ended December 31, 2010

	<u>2010 Fundraiser</u>	<u>2009 Fundraiser</u>
<b>REVENUES</b>		
Table sponsorships	\$55,813	\$57,450
Auction items	25,662	26,132
Donations	12,253	10,759
Ticket sales	10,650	10,430
Event novelties	280	-
Total revenues	<u>\$104,658</u>	<u>\$104,771</u>
<b>DIRECT FUNDRAISING EXPENSES</b>	<u>&lt;35,162&gt;</u>	<u>&lt;30,983&gt;</u>
<b>Amount raised for research</b>	<u>\$69,496</u>	<u>\$73,788</u>

June 30, 2011

## 16. Scotiabank Waterfront Marathon

In 2010, Fanconi Canada has undertaken a new fundraising event by entering a team in the Scotiabank Waterfront Marathon. The following details the success of the event.

### Scotiabank Waterfront Marathon Amount Raised for Research (Unaudited)

For the year ended December 31, 2010

	<u>2010</u>	<u>2009</u>
<b>REVENUES</b>		
Team and Individual Runner Sponsorships	\$11,201	-
<b>DIRECT FUNDRAISING EXPENSES</b>		
Registration and Fees	650	-
Team Novelties	225	-
Total Direct Fundraising Expenses	<u>875</u>	<u>-</u>
<b>Amount raised for research</b>	<u>\$10,326</u>	<u>-</u>